Jupiter Neurosciences Highlights Critical Advancement of 闯翱罢搁翱尝鈩� Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the significant advantages of its proprietary 闯翱罢搁翱尝鈩� platform over traditional resveratrol formulations. The company's breakthrough demonstrates 9x higher bioavailability compared to conventional resveratrol, without gastrointestinal side effects at therapeutic doses.
闯翱罢搁翱尝鈩� has shown ability to cross the blood-brain barrier and is advancing to Phase IIa trials for Parkinson's Disease. The platform's intellectual property is secured through 2036 across major markets. Jupiter plans to launch its Nugevia鈩� consumer product line in Q3 2025, featuring formulations for cognitive health, mitochondrial energy, and skin vitality.
Jupiter Neurosciences (NASDAQ: JUNS) ha evidenziato i vantaggi significativi della sua piattaforma proprietaria 闯翱罢搁翱尝鈩� rispetto alle formulazioni tradizionali di resveratrolo. L'innovazione dell'azienda dimostra una biodisponibilit脿 9 volte superiore rispetto al resveratrolo convenzionale, senza effetti collaterali gastrointestinali a dosi terapeutiche.
闯翱罢搁翱尝鈩� ha mostrato la capacit脿 di attraversare la barriera emato-encefalica ed 猫 in avanzamento verso trial di Fase IIa per il Morbo di Parkinson. La propriet脿 intellettuale della piattaforma 猫 protetta fino al 2036 nei principali mercati. Jupiter prevede di lanciare la sua linea di prodotti consumer Nugevia鈩� nel terzo trimestre 2025, con formulazioni dedicate alla salute cognitiva, all'energia mitocondriale e alla vitalit脿 della pelle.
Jupiter Neurosciences (NASDAQ: JUNS) ha destacado las ventajas significativas de su plataforma patentada 闯翱罢搁翱尝鈩� sobre las formulaciones tradicionales de resveratrol. El avance de la compa帽铆a demuestra una biodisponibilidad 9 veces mayor en comparaci贸n con el resveratrol convencional, sin efectos secundarios gastrointestinales a dosis terap茅uticas.
闯翱罢搁翱尝鈩� ha mostrado capacidad para cruzar la barrera hematoencef谩lica y est谩 avanzando hacia ensayos de Fase IIa para la Enfermedad de Parkinson. La propiedad intelectual de la plataforma est谩 asegurada hasta 2036 en los principales mercados. Jupiter planea lanzar su l铆nea de productos para consumidores Nugevia鈩� en el tercer trimestre de 2025, con formulaciones para la salud cognitiva, la energ铆a mitocondrial y la vitalidad de la piel.
Jupiter Neurosciences (NASDAQ: JUNS)電� 旮办〈 霠堨姢氩犽澕韸鸽· 鞝滍槙鞐� 牍勴暣 鞛愳偓鞚� 霃呾爯 頂岆灚韽� 闯翱罢搁翱尝鈩�鞚� 霙办柎雮� 鞛レ爯鞚� 臧曥“頄堨姷雼堧嫟. 鞚� 須岇偓鞚� 順侅嫚鞚� 旮办〈 霠堨姢氩犽澕韸鸽· 雽�牍� 9氚� 雴掛潃 靸濎泊鞚挫毄毳�鞚� 旃橂 鞖╇焿鞐愳劀 鞙勳灔 攵�鞛戩毄 鞐嗢澊 鞛呾頄堨姷雼堧嫟.
闯翱罢搁翱尝鈩㈧潃 順堧噷鞛ル步鞚� 韱店臣頃橂姅 電ル牓鞚� 氤挫榾鞙茧┌ 韺岉偍鞀硲 雽�靸� 2a靸� 鞛勳儊鞁滍棙鞙茧 歆勴枆 欷戩瀰雼堧嫟. 鞚� 頂岆灚韽检潣 歆�鞝� 鞛偘甓岇潃 欤检殧 鞁滌灔鞐愳劀 2036雲勱箤歆� 氤错樃霅╇媹雼�. Jupiter電� 鞚胳 瓯搓皶, 氙疙啝旖橂摐毽晞 鞐愲剤歆�, 頂茧秬 頇滊牓鞚� 鞙勴暅 鞝滍槙鞚� 韽暔頃� 靻岆箘鞛愳毄 鞝滍拡 霛检澑 Nugevia鈩㈦ゼ 2025雲� 3攵勱赴鞐� 於滌嫓頃� 瓿勴殟鞛呺媹雼�.
Jupiter Neurosciences (NASDAQ : JUNS) a mis en avant les avantages significatifs de sa plateforme propri茅taire 闯翱罢搁翱尝鈩� par rapport aux formulations traditionnelles de resv茅ratrol. L'innovation de la soci茅t茅 d茅montre une biodisponibilit茅 9 fois sup茅rieure 脿 celle du resv茅ratrol conventionnel, sans effets secondaires gastro-intestinaux aux doses th茅rapeutiques.
闯翱罢搁翱尝鈩� a montr茅 sa capacit茅 脿 traverser la barri猫re h茅mato-enc茅phalique et progresse vers des essais de phase IIa pour la maladie de Parkinson. La propri茅t茅 intellectuelle de la plateforme est prot茅g茅e jusqu'en 2036 sur les principaux march茅s. Jupiter pr茅voit de lancer sa ligne de produits grand public Nugevia鈩� au troisi猫me trimestre 2025, avec des formulations d茅di茅es 脿 la sant茅 cognitive, 脿 l'茅nergie mitochondriale et 脿 la vitalit茅 de la peau.
Jupiter Neurosciences (NASDAQ: JUNS) hat die bedeutenden Vorteile seiner propriet盲ren 闯翱罢搁翱尝鈩�-Plattform gegen眉ber herk枚mmlichen Resveratrol-Formulierungen hervorgehoben. Der Durchbruch des Unternehmens zeigt eine 9-fach h枚here Bioverf眉gbarkeit im Vergleich zu konventionellem Resveratrol, ohne gastrointestinale Nebenwirkungen bei therapeutischen Dosen.
闯翱罢搁翱尝鈩� hat die F盲higkeit gezeigt, die Blut-Hirn-Schranke zu 眉berwinden, und befindet sich in der Weiterentwicklung zu Phase-IIa-Studien f眉r die Parkinson-Krankheit. Das geistige Eigentum der Plattform ist bis 2036 in den wichtigsten M盲rkten gesichert. Jupiter plant die Einf眉hrung seiner Nugevia鈩�-Verbraucherproduktlinie im dritten Quartal 2025, mit Formulierungen f眉r kognitive Gesundheit, mitochondriale Energie und Hautvitalit盲t.
- None.
- Early clinical stage - still in Phase I/IIa development
- Efficacy in human trials for Parkinson's Disease not yet proven
Insights
闯翱罢搁翱尝鈩� solves resveratrol's bioavailability problem, advancing to Phase IIa for Parkinson's with strong commercial potential.
Jupiter Neurosciences has engineered a significant pharmaceutical advancement with 闯翱罢搁翱尝鈩�, addressing the fundamental limitations that have previously prevented resveratrol from becoming a viable therapeutic. The 9-fold increase in bioavailability demonstrated in Phase I trials represents a genuine breakthrough in drug delivery science, particularly for CNS applications. The ability to achieve therapeutic plasma concentrations without the dose-limiting GI toxicity seen with conventional formulations (>5g required for efficacy) is the critical distinction that gives this platform legitimate clinical potential.
Most important is JOTROL's demonstrated ability to cross the blood-brain barrier, which opens therapeutic pathways for neurological conditions where treatment options remain severely limited. The preclinical efficacy in the MPTP Parkinson's model showing motor improvements provides tangible evidence supporting their upcoming Phase IIa trial strategy. Their intellectual property position with protection through 2036 across major markets creates a substantial competitive moat.
The dual-track commercialization approach is particularly shrewd - developing high-value pharmaceutical applications while generating near-term revenue through consumer products. This strategy provides both cash flow potential and multiple shots on goal for shareholders. The mechanistic focus on mitochondrial biogenesis through AMPK/SIRT1 activation aligns with current scientific understanding of neurodegenerative pathways, giving their approach strong biological plausibility. While still early-stage, 闯翱罢搁翱尝鈩� represents a meaningful technological advancement with clear development pathways toward multiple CNS indications.
Transforming a promising molecule into a clinically viable therapeutic platform
Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL鈩�, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL鈩�, over conventional resveratrol formulations.
Unlocking Resveratrol鈥檚 Therapeutic Promise
Resveratrol is one of the world鈥檚 most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has proven elusive due to the molecule鈥檚 extremely poor bioavailability and dose-limiting gastrointestinal (GI) side effects.
鈥淐linical studies have shown that to reach the minimum effective plasma concentration of over 250 ng/mL a patient would need to ingest approximately 5 grams of today鈥檚 marketed resveratrol products,鈥� explained Christer Ros茅n, Chairman and CEO of Jupiter Neurosciences. 鈥淎t those levels, severe GI issues are nearly guaranteed, effectively halting any realistic therapeutic use.鈥�
A Pharmaceutical-Grade Breakthrough
JOTROL鈩� was developed specifically to overcome these critical limitations. In a Phase I clinical trial, JOTROL鈩� achieved a nine-fold increase in bioavailability compared to traditional resveratrol, without the GI toxicity seen at high doses. This proprietary formulation enables systemic therapeutic dosing with significantly reduced pill burden and enhanced tolerability.
Key Differentiators:
- Approximately 9 times higher bioavailability at peak plasma concentration versus na茂ve resveratrol
- No GI side effects observed at therapeutic levels
- Secured intellectual property in the U.S., EU, China, Japan, and Hong Kong through 2036
- Demonstrated ability to reach the central nervous system by passing the blood brain barrier, a critical factor for diseases such as Parkinson鈥檚, Alzheimer鈥檚, and MELAS
A Platform for Clinical Development and Commercial Growth
JOTROL鈩� is currently advancing toward a Phase IIa trial in Parkinson鈥檚 Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor functions. The same delivery technology is also being used in Jupiter鈥檚 Nugevia鈩� consumer product line, launching in Q3 2025 with targeted formulations focused on cognitive health (MND), mitochondrial energy (PWR), and skin vitality (GLO).
鈥淭his is more than just a formulation. It鈥檚 a platform,鈥� added Ros茅n. 鈥淲hether through pharmaceutical trials or premium consumer offerings, JOTROL鈩� opens entirely new pathways to address CNS diseases and longevity using the same foundational science.鈥�
Scientific Rationale: Targeting Mitochondria and Inflammation
As shown in Jupiter鈥檚 preclinical and mechanistic studies, resveratrol, and by extension JOTROL鈩�, works by promoting mitochondrial biogenesis through AMPK and SIRT1 activation. It also scavenges oxidative radicals and suppresses neuroinflammation. These mechanisms are increasingly recognized as central to the progression of neurodegenerative disease and systemic aging.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia鈩� product line. Both efforts are powered by JOTROL鈩�, Jupiter鈥檚 proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company鈥檚 prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson鈥檚 disease, includeing indications such as Alzheimer鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
About JOTROL
Resveratrol is one of the world鈥檚 most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL鈩� achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer鈥檚 Disease trial, and Yui et al., Friedreich鈥檚 Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL鈩� trials, were published in the Journal of Alzheimer鈥檚 Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL鈩� toward a Phase IIa trial in Parkinson鈥檚 Disease.
About Nugevia
In addition to its therapeutic applications, JOTROL鈩� serves as the foundation for Jupiter鈥檚 Nugevia鈩� consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia鈩� introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
The Nugevia product line will be launched in Q3 of 2025 through the website Nugevia.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
FAQ
What makes Jupiter Neurosciences' 闯翱罢搁翱尝鈩� different from traditional resveratrol?
What clinical trials is Jupiter Neurosciences (JUNS) conducting for 闯翱罢搁翱尝鈩�?
When will Jupiter Neurosciences (JUNS) launch its consumer products?
How long is 闯翱罢搁翱尝鈩�'s patent protection?
How does 闯翱罢搁翱尝鈩� work in treating neurological conditions?
